aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Vast Therapeutics, founded with a mission to address the global health crisis of drug-resistant infections, is a preclinical biotechnology company specializing in nitric oxide-based drugs. The company's vision is to combat severe chronic lung infections and improve patient outcomes using their proprietary technology. Their primary focus is on developing treatments for conditions such as bronchiectasis, NTM disease, and cystic fibrosis, targeting a market that urgently needs innovative solutions.
Notable figures associated with Vast Therapeutics include its scientific advisory board, comprised of experts in airway immunology and infectious diseases. The company has garnered attention for its innovative approach, evidenced by its selection to present at the American Thoracic Society's Respiratory Innovation Summit. Vast's impact lies in its potential to revolutionize treatment protocols for drug-resistant infections, contributing significantly to global health and economic stability.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Drugs
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Vast Therapeutics founded?
Vast Therapeutics was founded in 2017.
Where is Vast Therapeutics's headquarters located?
Vast Therapeutics's headquarters is located in Durham, NC, US.
When was Vast Therapeutics's last funding round?
Vast Therapeutics's most recent funding round was for $1.2M (USD) in November 2022.
How many employees does Vast Therapeutics have?
Vast Therapeutics has 35 employees as of Feb 4, 2024.
How much has Vast Therapeutics raised to-date?
As of July 05, 2023, Vast Therapeutics has raised a total of $16.2M (USD) since Nov 8, 2022.
Add Comparison
Total Raised to Date
$16.2M
USD
Last Update Nov 8, 2022
Last Deal Details
$1.2M
USD
Nov 8, 2022
Grant
Total Employees Over Time
35
As of Feb 2024
Vast Therapeutics Address
4222 Emperor Blvd
suite 470
Durham,
North Carolina
27703
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts